On Jan 27 2016, local biotech company InvitroCue made its debut on the Australian Securities Exchange (ASX: IVQ) - just four years after its founding. The company, a spin-off from A*STAR, just announced that it had raised an AUD 3.15 Million (SGD3.17 Million) on the ASX through a reverse takeover. In an exclusive one-on-one interview with Biotech Connection Singapore (BCS), the InvitroCue team (co-founders Dr Steven Fang, Prof Hanry Yu, and two of the first pioneering members, Dr. Abhishek Ananthanarayanan and Dr. Shuoyu Xu) shared their experience and appeal as a success formula for entrepreneurs in the local startup scene. BCS: Can you share with us what are the critical drivers underlying InvitroCue's success? InvitroCue: We focus on four components essential to every company's success – technology, market strategy, business model and leaders. Technology: We focus on two core technology developments – cell-based assay model and digital pathology. The beauty of our…